Hepatitis D Virus Antigen ELISA Kit

Name: Hepatitis D Virus Antigen ELISA Kit
SKU: DEIA073
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma

Species Reactivity

Human

Detection Method

sELISA

Intended Use

For the qualitative determination of human hepatitis D virus(HDV) antigen concentrations in serum, plasma.

Contents of Kit

1. Coated assay plate, 1(96 wells)
2. Negative Control, 1 × 1 ml
3. Positive Control, 1 × 1 ml
4. Antigen Lysate Buffer, 1 × 6 ml
5. HRP-conjugate, 1 × 6 ml
6. Wash Buffer (20× concentrate), 1 × 50 ml
7. Substrate A, 1 × 6 ml
8. Substrate B, 1 × 6 ml
9. Stop Solution, 1 × 6 ml
10. Adhesive Strip (For 96 wells), 4
11. Instruction manual, 1

Storage

Unopened kit: Store at 2 - 8°C. Do not use the kit beyond the expiration date.
Opened kit: May be stored for up to 2 weeks at 2 - 8°C.
*Provided this is within the expiration date of the kit.

Precision

Intra-assay Precision (Precision within an assay): CV%<15%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<15%
Three samples of known concentration were tested in twenty assays to assess.

Citations

Have you cited DEIA073 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Are hepatitis delta virus (HDV) genotypes important to determine the disease progression and therapy responses?

JOURNAL OF VIRAL HEPATITIS

Authors: Spaan, M.; Carey, I.; Bruce, M.; Shang, D.; Dusheiko, G.; Agarwal, K.

Abstract

Viral Hepatitis Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Authors: Lanini, Simone; Ustianowski, Andrew; Pisapia, Raffaella; Zumla, Alimuddin; Ippolito, Giuseppe

Abstract

Viral hepatitis is a major global public health problem affecting hundreds of millions of people and is associated with significant morbidity and mortality. Five major biologically unrelated hepatotropic viruses cause most of the global burden of viral hepatitis. Hepatitis B and hepatitis C are associated with a significant number of chronic infections. Most deaths from viral hepatitis are due to hepatitis B and hepatitis C. An estimated 257 million people were living with HBV and 71 million people were living with HCV. Most people are asymptomatic. New diagnostics and highly effective, pangenotypic direct-acting antivirals provide opportunities to cure and eradicate chronic hepatitis C virus infection.